Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amryt Pharma Plc ADR (NQ: AMYT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amryt Pharma Plc ADR

Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
From Amryt Pharma plc
Via GlobeNewswire
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
From Amryt Pharma plc
Via GlobeNewswire
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
From Amryt Pharma plc
Via GlobeNewswire
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
From Kahn Swick & Foti, LLC
Via Business Wire
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
From Amryt Pharma plc
Via GlobeNewswire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
From Kahn Swick & Foti, LLC
Via Business Wire
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
From Amryt Pharma plc
Via GlobeNewswire
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
From Amryt Pharma plc
Via GlobeNewswire
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
From Amryt Pharma plc
Via GlobeNewswire
European Commission approves Mycapssa® for the treatment of Acromegaly
From Amryt Pharma plc
Via GlobeNewswire
Amryt Announces New Patent for Mycapssa®
From Amryt Pharma plc
Via GlobeNewswire
Amryt Reports Q3 2022 Financial and Operational Results
From Amryt Pharma plc
Via GlobeNewswire
Amryt Supports Acromegaly Awareness Day 2022
From Amryt Pharma plc
Via GlobeNewswire
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa
From Amryt Pharma plc
Via GlobeNewswire
Amryt Supports Global EB Awareness Week 2022
From Amryt Pharma plc
Via GlobeNewswire
Amryt to Report Q3 2022 Results on November 3, 2022
From Amryt Pharma plc
Via GlobeNewswire
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
From Amryt Pharma plc
Via GlobeNewswire
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
From Amryt Pharma plc
Via GlobeNewswire
Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc. 
Via SBWire
Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 03/21/2022 -- Amryt Pharma plc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.